Skip to main content
NCBI home page
Scientific Reports logoLink to Scientific Reports
. 2020 Mar 11;10:4493. doi: 10.1038/s41598-020-61424-1

Nintedanib ameliorates animal model of dermatitis

Min-Jeong Heo 1, Chanmi Lee 1, Soo Young Choi 1, Yeong Min Choi 1, In-sook An 1, Seunghee Bae 2, Sungkwan An 2,✉, Jin Hyuk Jung 1,✉
PMCID: PMC7066145  PMID: 32161331

Abstract

Nintedanib, a receptor tyrosine kinase (RTK) inhibitor has been developed as therapeutics for idiopathic pulmonary fibrosis and non-small lung cancer. We found that the expression levels of RTK, especially VEGFR1 is increased in skin biopsies of dermatitis patients from multiple independent datasets. Moreover, VEGFR1 is highly expressed by infiltrated cells in dermis from oxazolone (OXA) treated mice. Interestingly, nintedanib alleviates dermatitis symptom in OXA-induced animal model. Especially, levels of epidermis thickness, infiltrated immune cells including mast cells and eosinophils were decreased from mice cotreated with nintedanib and OXA compared with OXA treated mice. Moreover, serum IgE and Th2 cytokines including IL-4 and IL-13 were decreased by nintedanib treatment. These results suggest an evidence that nintedanib alleviates animal model of dermatitis.

Subject terms: Target identification, Acute inflammation

Introduction

Receptor tyrosine kinases (RTKs) are membrane bound receptors for growth factors and hormones that modulate cellular process to have a crucial role in the development1,2. Because RTKs also often overexpressed in cancers including breast and non-small lung cancers, many inhibitors against RTKs have been developed for anticancer treatments3. On the other hands, tyrosine kinase mediates the signal from various immune related receptors including leukocyte antigen receptors, innate immune receptors, and cytokine receptors to activate immune cells and recruit to inflammation lesion4. Autoimmune and inflammatory diseases are characterized by inflammatory microenvironment and tyrosine kinase serves essential role in immune-mediated disorders5. Therefore, small molecules targeting tyrosine kinase have been developed for autoimmune and inflammatory diseases6–8. Especially JAK is a one of primary tyrosine kinases for therapeutic target since JAK is responsible for numerous cytokines expression via type I/II cytokine receptor signaling9–11. Many JAK inhibitors are FDA approved in clinic use for autoimmune and inflammatory diseases12. Atopic dermatitis (AD) is one of the most common skin inflammatory diseases affecting 3–10% adults and 15–20% of children in USA13–15. AD pathogenesis is a complex of skin barrier dysfunction, alteration of immune responses, IgE-mediated hypersensitivity16,17. Treatments of atopic dermatitis are non-specific immunosuppressants and Th2 specific therapies including biologics18–20. Because IL-4, which is a primary pathogenic in AD requires JAK1 and 3 with additional complex, JAK inhibitors including tofacitinib and baricitinib have been determined their efficacy on the AD21–23. VEGFR1 is a receptor of VEGF, transduces a signal to induce angiogenesis and lymphangiogenesis24,25. Dilated vessels and perivascular edema are frequently found in AD lesion with erythema26,27. Moreover, increased levels of VEGF are found in plasma and AD lesion28,29. Although VEGF-VEGFR signaling is highly activated in AD, use of VEGFR inhibitor for AD treatment remains unexplored. Interestingly, we found expression levels of RTKs are upregulated in skin biopsies of dermatitis patients from several independent datasets (Fig. 1 and Table S1). Nintedanib is a potent receptor kinase inhibitor that competitively binds to the kinase domains of vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor beta (PDGFRB) and fibroblast growth factor receptor (FGFR)30. Nintedanib is a FDA-approved oral drug for idiopathic pulmonary fibrosis (IPF)31. Here we used nintedanib to determine whether nintedanib attenuates oxazolone-induced animal model of dermatitis.

Figure 1.

Figure 1

Open in a new tab

The expression levels of VEGFR1/FLT1 in animal model of dermatitis and dermatitis patients. (a) Relative expression levels of FLT1 in normal (n = 121) and dermatitis patients (n = 128). (b) mRNA expression of Flt1 was measured in oxazolone (OXA) treated mice ear and vehicle control (n = 15). (c) Histological analysis (H&E, Sirius red and toluidine blue staining) of control and oxazolone treated mice ear. Scale bar = 100 μm. (d) Immunofluorescent analysis of VEGFR1 from control and oxazolone treated mice ear. Scale bar = 100 μm. Data are presented as mean ± SEM and analyzed by student t-test. *p  <  0.05, **p  <  0.01 compared to control.

Material and Methods

All methods were performed in accordance with the relevant guidelines and regulations.

Experimental animals

7-week-old BALB/c mice were purchased from the Central Laboratory Animals (Seoul, Korea). They were feed and raised under specific pathogen-free conditions with 12 h light/dark cycle in controlled environment condition as temperature and humidity. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the Konkuk University (KU19160).

OXA-induced murine model of dermatitis

To induce AD-like lesion, all ears of mice except the negative control group were applied with oxazolone (OXA). OXA-induced animal model of dermatitis was performed according to previously described with some modifications32,33. Briefly, skin inflammation was induced by topical administration with 30 μl of 1% OXA dissolved in acetone (Merck, Kenilworth, USA) on day 0, and repeated 30 μl of 0.2% OXA three times a week from day 7 to 21. Negative control group was treated same volume of vehicles. Therapeutic groups as 0.68 mg/kg dexamethasone (DEX) or 7 mg/kg Nintedanib (NIN) were applied on ear after 1 h every challenge. Drug administration was performed under light anesthesia with isoflurane. Detailed description is as shown Fig. 2a. Mice were photographed by Digital Single-Lens Reflex camera (Conditions; F5.6 1/40, ISO800; Canon, Tokyo, Japan).

Figure 2.

Figure 2

Open in a new tab

Morphological analysis of nintedanib-treated mice. (a) Schematic diagram of oxazolone (OXA)-induced animal model. Four groups: untreated controls, OXA only and mice treated with DEX (Dexamethasone) or nintedanib (NIN) one hour after every OXA challenge. (b) Representative photographs of mouse ears from each group on day 0 and 21. (c) Ear thickness was measured every week as indicated. Data are from three independent experiments (n = 15). Data are presented as mean  ±  SEM. Data (Day 21) are analyzed by student t-test. ***p  <  0.005 compared to oxazolone treated. (d) Ear weight was measured at day 21. Data are from three independent experiments (n = 15). Data are presented as mean  ±  SEM and analyzed by one-way ANOVA (****p < 0.001 compared to control, ##p < 0.01, ###p < 0.005 compared to oxazolone treated).

Ear thickness and ear weight

Ear thickness was measured every other day using digital micrometer (Japan), and ear was collected using 5-mm biopsy punch (KAI Medical, Japan) after sacrifice for measuring weight on day 21.

Histology

Ear tissues were fixed in 10% formalin solution (Sigma, Mo, USA) for 24 h. Tissues were washed with PBS (Biosesang, Seongnam, Korea), embedded in paraffin (Leica Biosystems, Wetzlar, Germany) and sectioned 4 μm thickness using microtome (HistoCore BIOCUT; Leica Biosystems, Germany). Stained images were taken using light microscope (Olympus, Tokyo, Japan). Mast cells or eosinophils were counted in 3 random high-power field (HPF) each mouse at 400× magnification. H&E staining was performed according to previously described34. Epidermis and dermis thickness were measured using imageJ software program. Toluidine blue staining was used to count infiltrated mast cells. Briefly, hydrated tissue sections were stained with 0.1% Toluidine Blue O in 1% sodium chloride solution (pH 2; Sigma, USA) for 1 min. After staining, sections were washed briefly in PBS, and dehydration 3 times with 95% to 100% ethanol, and then sealed using mounting medium35. Sirius Red staining was used to count the number of infiltrated eosinophil cells36. Reagent preparation and staining protocol were according to previously as described37.

Cells and reagents

NIH3T3/NKκB-luc cell line was purchased from Panomics (RC0015). Cells were maintained in a humidified incubator at 37 °C and 5% CO2. FBMTM-2 Fibroblast Growth Medium-2 BulletKitTM was purchased from Lonza (CC-3132, Lonza). Recombinant Human TNF-alpha was purchased from Peprotech (300-01A-10, Peprotech). Bay was purchased from Sigma (11-7082, Sigma). Nintedanib was purchased from Cayman chemical (11022).

Cell viability assay

Viability was performed as previously described with slight modification38. Briefly, 1 × 104 cells were plated in a 96 well plate. Pre-incubate the plate for 24 h in a humidified incubator. After nintedanib treatment, cells were incubated with mixture (1:10) of EZ-Cytox cell viability assay kit (Dogen, EZ3000). Then plate was incubated for 30 min in the incubator and determined absorbance at 450 nm with reference to 655 nm wavelength (iMark, Biorad).

Luciferase assay

Luciferase assay was performed as previously described with slight modification39. 6 × 105 cells were seeded in 24-well plates treated 50 nM TNF-α for 8 h with or without nintedanib. Cells were harvested and cell extracts were prepared using 100 μl of passive lysis buffer (Promega). Luciferase activities were measured using Veritas Luminometer (Turnur Designs, Sunnyvale, CA, USA).

Web-based meta-analysis

Microarray datasets from studies (GSE6002840, GSE7915041, GSE3684242, GSE46239, GSE3292443, GSE12121244, GSE1616145, GSE12072146 and GSE10736147 were analyzed using GEO2R (https://www.ncbi.nlm.nih.gov/geo/geo2r) to determine enzyme expression of RTK.

Serum IgE ELISA

Serum was collected from the abdominal aorta of mice. Whole blood was placed during 30 min at room temperature and centrifuged at 4 °C for 15 min at ×12,000 rpm. The supernatant was stored immediately at −80 °C. For analysis, samples were diluted to 1/200 with assay diluent. Total IgE were determined by ELISA kit according to manufacturer’s manual (BD Pharmingen; San Diego, CA, USA). All measurements were analyzed by optical density at 450 nm.

RNA isolation and RT-PCR

Mice ear was homogenized in 1 ml of TRIzol reagent (Takara Co., Ltd. Japan) using IKA-T10 basic homogenizer (ULTRA-TURRAX; 10 mm; IKA Laboratory Equipment, Staufen, Germany). Total RNA was isolated previously described48. Total RNA was quantified by MaestroNano Micro-Volume Spectrophotometer (Xiangshan Diist, Taiwan) and 300 ng RNA was used for reverse transcription using M-MLV reverse transcriptase (Invitrogen, California, USA). Real-time PCR analysis was performed with duplicate using SYBR® Master Mix in the BIOER Real-Time PCR machine (Fluorescent Quantitative Detection systems; Hangzhou, China). For calculation efficiency of the amplification, the relative quantitative of each target gene was normalized to the housekeeping gene as β-Actin. Data was calculated by the 2− ΔΔCT method based on the normalization gene of control group.

Immunofluorescence

Immunofluorescence was performed using a heat-induced epitope retrieval (HIER) protocol with slight modification49. After deparaffinization, slides were placed in a plastic container filled with citrate buffer, pH 6.0 at 60 °C for 20 min. And then, slides were allowed to cool for 20 min at room temperature and were then rinsed with phosphate-buffered saline with Tween 20 (PBST, Duchefa Biochemie, Hofmanweg, Netherlands). Slides were incubated in blocking buffer (BLOXALL® Endogenous Peroxidase and Alkaline Phosphatase Blocking Solution, Vector Laboratories, Inc., California, USA) for 1 h at room temperature to remove non-specific binding. Next, they were incubated for 24 h with Flt1 (VEGFR1) antibody (Santacruz biotechnology, Texas, USA) in blocking buffer at 4 °C. Next day, the slides were washed and incubated for 1 h at room temperature with anti-mouse secondary antibodies conjugated with Alexa Flour 647 (Abcam, Cambridge, United Kingdom). The slides were counterstained with DAPI for 10 min and mounted with fluorescence mounting medium (Agilent, California, USA).

Statistical analysis

All statistical evaluations were performed using Prism 6 (GraphPad Software, La Jolla, CA). Data are given as mean ± standard error of the mean (SEM). Statistical significance was analyzed using Student’s t-test and one-way ANOVA. P values of <0.05, <0.01 and <0.001 were considered as statistically significant differences.

Ethics approval and consent to participate

All animals were care for by using protocols approved by the Institutional Animal Care and Use Committee (Konkuk University, Republic of Korea). No. KU10160.

Results

Vascular endothelial growth factor receptor1 (VEGFR1) is highly expressed in atopic dermatitis lesion

We determined the levels of RTKs (VEGFR1, PDGFRB and FGFR2) from dermatitis patients and normal controls using meta-analyses. Interestingly, the expression levels of VEGFR1 were increased from ten studies from seven independent datasets of lesion from dermatitis patients compared with control subjects (Fig. 1a and. Table S1) (GSE6002840, GSE7915041, GSE3684242, GSE46239, GSE3292443, GSE12121244, GSE1616145). We found PDGFRB and FGFR2 were increased from dermatitis patients compared to normal control (Table S1). Moreover, we found the levels of VEGFR1 are increased in oxazolone (OXA) treated mice (Fig. 1b). Consequently, VEGFR1 was increased by infiltrated cells in dermis of OXA treated mice (Fig. 1c,d). These results indicated that expression of RTKs, especially VEGFR1 is increased in dermis of atopic dermatitis lesion.

Nintedanib ameliorates dermatitis in OXA-induced animal model

To determine whether nintedanib, RTK inhibitor is effective on dermatitis, we employed OXA-induced mice model (Fig. 2a). We found nintedanib treatment is able to attenuate morphological phenotype including skin redness and swelling of OXA-induced skin inflammation (Fig. 2b). Moreover, the levels of ear thickness and weight robustly decreased from mice cotreated with nintedanib and OXA compared to OXA-treated mice (Fig. 2c,d).

Nintedanib attenuates OXA-induced dermatitis in histological analysis

We found epidermis and dermis thickness are decreased from mice cotreated with nintedanib and OXA using histological analysis (Fig. 3a,b). Interestingly, numbers of infiltrated mast cells as well as eosinophils into dermis were decreased from mice cotreated with nintedanib and OXA compared to OXA-treated (Fig. 3d,e). Moreover, serum IgE levels were decreased from mice cotreated with nintedanib and OXA compared to OXA-treated mice (Fig. 3f). These results indicated that topical administration of nintedanib ameliorates OXA-induced dermatitis by histological analysis.

Figure 3.

Figure 3

Open in a new tab

Histological analysis of nintedanib-treated mice. (a) H&E, sirius red and toluidine blue staining in ear lesions. Scale bar = 50 μm (b) Mean of epidermal thickness was measured using three different sections. (c) Mean of epidermal thickness was measured using three different sections. (d) Mean of mast cells (black arrow in toluidine blue staining) in dermis was measured. (e) Mean of eosinophil cells (red arrow in sirius red staining) in dermis was measured. (f) Serum IgE level was measured by ELISA at day 21. Data are from three independent experiments (n = 15). Data are presented as mean  ±  SEM of changes in values and analyzed by one-way ANOVA (**p < 0.01, ***p < 0.005, ****p < 0.001 compared to control, #p < 0.05, ##p < 0.01, ###p < 0.005, ####p < 0.001 compared to oxazolone treated).

Nintedanib attenuates cytokine expression in OXA-induced model of dermatitis

Th2-type cytokines including IL-4 and IL-13 are one of the typical markers as well as therapeutic targets of atopic dermatitis20. We therefore, analyzed expression of cytokines from mice ear to determine whether nintedanib attenuates immune response. Interestingly, Th2 cytokines including IL-4, IL-5, IL-6, and IL-13 were decreased from mice cotreated nintedanib with OXA while there was no change on the expression of Th1 cytokines including TNF-α, IL-1β and IFN-γ (Fig. 4a–h). These results indicated that nintedanib attenuates Th2-type immune response in oxazolone-induced animal model of dermatitis. In order to determine the molecular mechanism of nintedanib-mediated anti-inflammatory effect, we used 3T3 murine fibroblasts, which stably expressed luciferase reporter plasmid encoded with NFκB-binding motif. Because 100 nM nintedanib-treated fibroblasts showed 91% viability, 50 nM and 100 nM nintedanib were used to measure NFκB activity in presence of TNF-α (Fig. S2a). We found that nintedanib is not able to modulate NFκB activity (Fig. S2b). These results indicated that NFκB may not be the primary molecular signaling pathway for nintedanib to inhibit oxazolone-induced animal model of dermatitis.

Figure 4.

Figure 4

Open in a new tab

Expression of cytokines in nintedanib-treated mice. (a) mRNA levels of TNF-α from indicated mice ear. (b) mRNA levels of IL-β from indicated mice ear. (c) mRNA levels of IFN-γ from indicated mice ear. (d) mRNA levels of IL-4 from indicated mice ear. (e) mRNA levels of IL-5 from indicated mice ear. (f) mRNA levels of IL-6 from indicated mice ear. (g) mRNA levels of IL-10 from indicated mice ear. (h) mRNA levels of IL-13 from indicated mice ear. Data are from three independent experiments (n = 15). Data are presented as mean  ±  SEM and analyzed by one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.005 versus control) and (#p < 0.05, ##p < 0.01 versus OXA).

Discussion

We found the expression levels of RTKs especially, VEGFR are increased in the lesion of dermatitis patients (Fig. 1a and Table S1). There are numerous reports that VEGFR is highly expressed during inflammation and further studies are required to determine the role of VEGFR in lesion of dermatitis patients50–52. Moreover, systemic anti-VEGF treatments strongly reduced skin inflammation in a mice model of psoriasis53. Those observations drove us to use nintedanib a potent FDA approved RTK inhibitor to determine therapeutic efficacy in animal model of dermatitis. We found that nintedanib treatment attenuates phenotype of oxazolone-induced skin inflammation in animal model without toxicity (Figs. 2b and S1). Histological analysis showed that nintedanib reduces infiltrated immune cells including mast cells and eosinophils (Fig. 3d,e). Moreover, the levels of Th2-type cytokines expression including IL-4 and IL-13 were reduced from nintedanib with OXA treated mice ear compared to OXA-treated (Fig. 4d-h). NFκB signaling is an important signaling pathway that orchestrates inflammatory response54. We found that nintedanib is not able to attenuate NFκB activity in presence of TNF-α (Fig. S2a,b). According to recent reports, nintedanib inhibits angiogenesis, reduced M (IL-4) cell polarization and induces apoptosis of mesenchymal cells during fibrotic remodeling55–58. Thus, we speculated that nintedanib may regulate migration of inflammatory cells into the AD lesion by inhibiting angiogenesis, and/or immune cells polarization. Adverse effects of topical use of steroid-containing cream have been well established59,60. Although, novel drugs have been developed for dermatitis therapeutics including PDE4 inhibitors and JAK inhibitors, high costs of new drugs are one of the major burdens while dermatitis patients are increasing every year61,62. Therefore, repurposing drugs may cover these limitations of atopic dermatitis therapeutics. And nintedanib could be a one of the primary candidates as a repurposing drug because effects of nintedanib on air way inflammation is reported beyond current indication63. Future studies are remains to be explored to determine molecular mechanism of nintedanib-mediated anti-inflammatory effect on dermatitis.

Supplementary information

Supplementary information. (216.5KB, pdf)

Acknowledgements

We thank Na kyung Jeong for assisting mast cell count in histological analysis. This work is supported by the GeneCellPharm Corporation.

Author contributions

M.J.H., S.Y.C., C.M.L., Y.M.C. and J.H.J designed the experiments and analyzed the data. M.J.H., S.Y.C. and C.M.L. performed the experiments. M.J.H., J.H.J. and S.B. wrote the manuscript. S.A. and I.S.A. supported research grant.

Data availability

All study data are available from the corresponding author upon request.

Competing interests

The authors declare no competing interests.

Footnotes

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Contributor Information

Sungkwan An, Email: ansungkwan@konkuk.ac.kr.

Jin Hyuk Jung, Email: jungjh@skinreseach.or.kr.

Supplementary information

is available for this paper at 10.1038/s41598-020-61424-1.

References

  • 1.Lemmon MA, Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2010;141:1117–1134. doi: 10.1016/j.cell.2010.06.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Schlessinger J. Cell signaling by receptor tyrosine kinases. Cell. 2000;103:211–225. doi: 10.1016/s0092-8674(00)00114-8. [DOI] [PubMed] [Google Scholar]
  • 3.Regad T, Targeting RTK. Signaling Pathways in Cancer. Cancers. 2015;7:1758–1784. doi: 10.3390/cancers7030860. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Szilveszter KP, Nemeth T, Mocsai A. Tyrosine Kinases in Autoimmune and Inflammatory Skin Diseases. Front. Immunol. 2019;10:1862. doi: 10.3389/fimmu.2019.01862. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Mocsai A, Kovacs L, Gergely P. What is the future of targeted therapy in rheumatology: biologics or small molecules? BMC Med. 2014;12:43. doi: 10.1186/1741-7015-12-43. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Ghoreschi K, Gadina M. Jakpot! New small molecules in autoimmune and inflammatory diseases. Exp. Dermatol. 2014;23:7–11. doi: 10.1111/exd.12265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Virtanen AT, Haikarainen T, Raivola J, Silvennoinen O. Selective JAKinibs: Prospects in Inflammatory and Autoimmune Diseases. BioDrugs. 2019;33:15–32. doi: 10.1007/s40259-019-00333-w. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Bhagwat SS. Kinase inhibitors for the treatment of inflammatory and autoimmune disorders. Purinergic Signal. 2009;5:107–115. doi: 10.1007/s11302-008-9117-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Pesu M, et al. Therapeutic targeting of Janus kinases. Immunol. Rev. 2008;223:132–142. doi: 10.1111/j.1600-065X.2008.00644.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Ghoreschi K, Laurence A, O’Shea JJ. Janus kinases in immune cell signaling. Immunol. Rev. 2009;228:273–287. doi: 10.1111/j.1600-065X.2008.00754.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.O’Shea JJ, Kontzias A, Yamaoka K, Tanaka Y, Laurence A. Janus kinase inhibitors in autoimmune diseases. Ann. Rheum. Dis. 2013;72(Suppl 2):ii111–115. doi: 10.1136/annrheumdis-2012-202576. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12.Moran N. Incyte comes of age with JAK inhibitor approval. Nat. Biotechnol. 2012;30:3–5. doi: 10.1038/nbt0112-3. [DOI] [PubMed] [Google Scholar]
  • 13.Leung DY. New insights into atopic dermatitis: role of skin barrier and immune dysregulation. Allergol. Int. 2013;62:151–161. doi: 10.2332/allergolint.13-RAI-0564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ricci G, Dondi A, Patrizi A, Masi M. Systemic therapy of atopic dermatitis in children. Drugs. 2009;69:297–306. doi: 10.2165/00003495-200969030-00005. [DOI] [PubMed] [Google Scholar]
  • 15.Bieber T. Atopic dermatitis. N. Engl. J. Med. 2008;358:1483–1494. doi: 10.1056/NEJMra074081. [DOI] [PubMed] [Google Scholar]
  • 16.David Boothe W, Tarbox JA, Tarbox MB. Atopic Dermatitis: Pathophysiology. Adv. Exp. Med. Biol. 2017;1027:21–37. doi: 10.1007/978-3-319-64804-0_3. [DOI] [PubMed] [Google Scholar]
  • 17.McPherson T. Current Understanding in Pathogenesis of Atopic Dermatitis. Indian. J. Dermatol. 2016;61:649–655. doi: 10.4103/0019-5154.193674. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Hajar T, Gontijo JRV, Hanifin JM. New and developing therapies for atopic dermatitis. An. Bras. Dermatol. 2018;93:104–107. doi: 10.1590/abd1806-4841.20187682. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Werfel T, et al. Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. J. Allergy Clin. Immunol. 2016;138:336–349. doi: 10.1016/j.jaci.2016.06.010. [DOI] [PubMed] [Google Scholar]
  • 20.Brunner PM, Guttman-Yassky E, Leung DY. The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. J. Allergy Clin. Immunol. 2017;139:S65–S76. doi: 10.1016/j.jaci.2017.01.011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Stritesky GL, et al. The transcription factor STAT3 is required for T helper 2 cell development. Immun. 2011;34:39–49. doi: 10.1016/j.immuni.2010.12.013. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Takeda K, et al. Essential role of Stat6 in IL-4 signalling. Nat. 1996;380:627–630. doi: 10.1038/380627a0. [DOI] [PubMed] [Google Scholar]
  • 23.Bao L, Zhang H, Chan LS. The involvement of the JAK-STAT signaling pathway in chronic inflammatory skin disease atopic dermatitis. JAKSTAT. 2013;2:e24137. doi: 10.4161/jkst.24137. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Shibuya M. Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes. Cancer. 2011;2:1097–1105. doi: 10.1177/1947601911423031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Koch S, Claesson-Welsh L. Signal transduction by vascular endothelial growth factor receptors. Cold Spring Harb. Perspect. Med. 2012;2:a006502. doi: 10.1101/cshperspect.a006502. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Agha-Majzoub R, Becker RP, Schraufnagel DE, Chan LS. Angiogenesis: the major abnormality of the keratin-14 IL-4 transgenic mouse model of atopic dermatitis. Microcirculation. 2005;12:455–476. doi: 10.1080/10739680591003297. [DOI] [PubMed] [Google Scholar]
  • 27.Thomsen SF. Atopic dermatitis: natural history, diagnosis, and treatment. ISRN Allergy. 2014;2014:354250. doi: 10.1155/2014/354250. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Koczy-Baron E, Jochem J, Kasperska-Zajac A. Increased plasma concentration of vascular endothelial growth factor in patients with atopic dermatitis and its relation to disease severity and platelet activation. Inflamm. Res. 2012;61:1405–1409. doi: 10.1007/s00011-012-0543-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Zhang Y, Matsuo H, Morita E. Increased production of vascular endothelial growth factor in the lesions of atopic dermatitis. Arch. Dermatol. Res. 2006;297:425–429. doi: 10.1007/s00403-006-0641-9. [DOI] [PubMed] [Google Scholar]
  • 30.Wollin L, et al. Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis. Eur. Respir. J. 2015;45:1434–1445. doi: 10.1183/09031936.00174914. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 31.Keating GM. Nintedanib: A Review of Its Use in Patients with Idiopathic Pulmonary Fibrosis. Drugs. 2015;75:1131–1140. doi: 10.1007/s40265-015-0418-6. [DOI] [PubMed] [Google Scholar]
  • 32.Lee S, et al. Ameliorative effects of Juniperus rigida fruit on oxazolone- and 2,4-dinitrochlorobenzene-induced atopic dermatitis in mice. J. Ethnopharmacol. 2018;214:160–167. doi: 10.1016/j.jep.2017.12.022. [DOI] [PubMed] [Google Scholar]
  • 33.Choi Soo Young, Heo Min-Jeong, Lee Chanmi, Choi Yeong Min, An In-sook, Bae Seunghee, An Sungkwan, Jung Jin Hyuk. 2-deoxy-d-glucose Ameliorates Animal Models of Dermatitis. Biomedicines. 2020;8(2):20. doi: 10.3390/biomedicines8020020. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Jung JH, Wang XD, Loeken MR. Mouse embryonic stem cells established in physiological-glucose media express the high KM Glut2 glucose transporter expressed by normal embryos. Stem Cell Transl. Med. 2013;2:929–934. doi: 10.5966/sctm.2013-0093. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Oishi N, et al. Expression of precipitating factors of pruritus found in humans in an imiquimod-induced psoriasis mouse model. Heliyon. 2019;5:e01981. doi: 10.1016/j.heliyon.2019.e01981. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36.Meyerholz DK, Griffin MA, Castilow EM, Varga SM. Comparison of histochemical methods for murine eosinophil detection in an RSV vaccine-enhanced inflammation model. Toxicol. Pathol. 2009;37:249–255. doi: 10.1177/0192623308329342. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 37.Schmitz N, Laverty S, Kraus VB, Aigner T. Basic methods in histopathology of joint tissues. Osteoarthr. Cartil. 2010;18(Suppl 3):S113–116. doi: 10.1016/j.joca.2010.05.026. [DOI] [PubMed] [Google Scholar]
  • 38.Jung JH, et al. Triad 1 induces apoptosis by p53 activation. FEBS Lett. 2010;584:1565–1570. doi: 10.1016/j.febslet.2010.03.011. [DOI] [PubMed] [Google Scholar]
  • 39.Jung JH, et al. E3 ubiquitin ligase Hades negatively regulates the exonuclear function of p53. Cell Death Differ. 2011;18:1865–1875. doi: 10.1038/cdd.2011.57. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Dhingra N, et al. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response. J. Allergy Clin. Immunol. 2014;134:362–372. doi: 10.1016/j.jaci.2014.03.009. [DOI] [PubMed] [Google Scholar]
  • 41.Blok JL, Li K, Brodmerkel C, Jonkman MF, Horvath B. Gene expression profiling of skin and blood in hidradenitis suppurativa. Br. J. Dermatol. 2016;174:1392–1394. doi: 10.1111/bjd.14371. [DOI] [PubMed] [Google Scholar]
  • 42.Gittler JK, et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J. Allergy Clin. Immunol. 2012;130:1344–1354. doi: 10.1016/j.jaci.2012.07.012. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 43.Suarez-Farinas M, et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J. Allergy Clin. Immunol. 2011;127(954–964):e951–954. doi: 10.1016/j.jaci.2010.12.1124. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44.Tsoi LC, et al. Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis. J. Invest. Dermatol. 2019;139:1480–1489. doi: 10.1016/j.jid.2018.12.018. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Guttman-Yassky E, et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J. Allergy Clin. Immunol. 2009;124:1235–1244 e1258. doi: 10.1016/j.jaci.2009.09.031. [DOI] [PubMed] [Google Scholar]
  • 46.Esaki H, et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J. Allergy Clin. Immunol. 2015;135:153–163. doi: 10.1016/j.jaci.2014.10.037. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Brunner PM, et al. Early-onset pediatric atopic dermatitis is characterized by TH2/TH17/TH22-centered inflammation and lipid alterations. J. Allergy Clin. Immunol. 2018;141:2094–2106. doi: 10.1016/j.jaci.2018.02.040. [DOI] [PubMed] [Google Scholar]
  • 48.Choi YM, An S, Bae S, Jung JH. Mdm2 is required for HDAC3 monoubiquitination and stability. Biochem. Biophys. Res. Commun. 2019;517:353–358. doi: 10.1016/j.bbrc.2019.07.052. [DOI] [PubMed] [Google Scholar]
  • 49.Parra ER, et al. Validation of multiplex immunofluorescence panels using multispectral microscopy for immune-profiling of formalin-fixed and paraffin-embedded human tumor tissues. Sci. Rep. 2017;7:13380. doi: 10.1038/s41598-017-13942-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Waldner MJ, et al. VEGF receptor signaling links inflammation and tumorigenesis in colitis-associated cancer. J. Exp. Med. 2010;207:2855–2868. doi: 10.1084/jem.20100438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Angelo LS, Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clin. Cancer Res. 2007;13:2825–2830. doi: 10.1158/1078-0432.CCR-06-2416. [DOI] [PubMed] [Google Scholar]
  • 52.Huggenberger R, et al. Stimulation of lymphangiogenesis via VEGFR-3 inhibits chronic skin inflammation. J. Exp. Med. 2010;207:2255–2269. doi: 10.1084/jem.20100559. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 53.Schonthaler HB, Huggenberger R, Wculek SK, Detmar M, Wagner EF. Systemic anti-VEGF treatment strongly reduces skin inflammation in a mouse model of psoriasis. Proc. Natl Acad. Sci. USA. 2009;106:21264–21269. doi: 10.1073/pnas.0907550106. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Liu, T., Zhang, L., Joo, D. & Sun, S. C. NF-kappaB signaling in inflammation. Signal Transduct Target Ther2, 10.1038/sigtrans.2017.23 (2017). [DOI] [PMC free article] [PubMed]
  • 55.Cipriani P, et al. Differential expression of stromal cell-derived factor 1 and its receptor CXCR4 in the skin and endothelial cells of systemic sclerosis patients: Pathogenetic implications. Arthritis Rheum. 2006;54:3022–3033. doi: 10.1002/art.22047. [DOI] [PubMed] [Google Scholar]
  • 56.da Silva RF, et al. Nintedanib antiangiogenic inhibitor effectiveness in delaying adenocarcinoma progression in Transgenic Adenocarcinoma of the Mouse Prostate (TRAMP) J. Biomed. Sci. 2017;24:31. doi: 10.1186/s12929-017-0334-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 57.Roth GJ, et al. Nintedanib: from discovery to the clinic. J. Med. Chem. 2015;58:1053–1063. doi: 10.1021/jm501562a. [DOI] [PubMed] [Google Scholar]
  • 58.Kasam RK, Reddy GB, Jegga AG, Madala SK. Dysregulation of Mesenchymal Cell Survival Pathways in Severe Fibrotic Lung Disease: The Effect of Nintedanib Therapy. Front. Pharmacol. 2019;10:532. doi: 10.3389/fphar.2019.00532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 59.Fisher DA. Adverse effects of topical corticosteroid use. West. J. Med. 1995;162:123–126. [PMC free article] [PubMed] [Google Scholar]
  • 60.Hengge Ulrich R., Ruzicka Thomas, Schwartz Robert A., Cork Michael J. Adverse effects of topical glucocorticosteroids. Journal of the American Academy of Dermatology. 2006;54(1):1–15. doi: 10.1016/j.jaad.2005.01.010. [DOI] [PubMed] [Google Scholar]
  • 61.Cotter DG, Schairer D, Eichenfield L. Emerging therapies for atopic dermatitis: JAK inhibitors. J. Am. Acad. Dermatol. 2018;78:S53–S62. doi: 10.1016/j.jaad.2017.12.019. [DOI] [PubMed] [Google Scholar]
  • 62.Clark R, et al. Topical treatment utilization for patients with atopic dermatitis in the United States, and budget impact analysis of crisaborole ointment, 2. J. Med. Econ. 2018;21:770–777. doi: 10.1080/13696998.2018.1470520. [DOI] [PubMed] [Google Scholar]
  • 63.Lee J, et al. Effect of nintedanib on airway inflammation in a mouse model of acute asthma. J. Asthma. 2020;57:11–20. doi: 10.1080/02770903.2018.1544641. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Supplementary information. (216.5KB, pdf)

Data Availability Statement

All study data are available from the corresponding author upon request.

Articles from Scientific Reports are provided here courtesy of Nature Publishing Group

RESOURCES